Reviews

Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test

The development of effective preventive therapies has been hampered by a lack of understanding concerning the pathobiological mechanisms underlying cytotoxic therapy–induced mucositis.


 

Gastrointestinal mucosal toxicity is extremely common following cytotoxic therapies. The alimentary mucosa is particularly susceptible to injury and dysfunction, leading to many debilitating complications. Despite much research, there is currently no single noninvasive biomarker to detect gut injury. Several biomarkers have been investigated in the context of gastrointestinal diseases, which may prove useful in the oncology arena. Identification of a biomarker that is easy to obtain and measure and that accurately identifies mucosal damage would allow for improved patient diagnosis of toxicities and for personalized treatment regimens. In this review, we highlight the effectiveness of urine and breath tests as potential clinically effective biomarkers, with significant focus placed on the emerging role of the carbon-13 sucrose breath test (13C SBT). The 13C SBT provides a simple, noninvasive, and integrated measure of gut function. The 13C SBT also has the potential to monitor gut function in the setting of cytotoxic therapy–induced mucositis, or in the assessment of the efficacy of antimucositis agents.

*For a PDF of the full article, click on the link to the left of this introduction.

Recommended Reading

Dexamethasone eases end-of-life cancer-related fatigue
MDedge Hematology and Oncology
USPSTF draft recommendations update chemoprevention for breast cancer
MDedge Hematology and Oncology
SPIKES protocol offers guidance for 'active listening' when talking to cancer patients
MDedge Hematology and Oncology
Weight loss, exercise can impact cancer incidence and recurrence
MDedge Hematology and Oncology
Timely palliative consult affects end-of-life care in gynecologic cancer patients
MDedge Hematology and Oncology
Resistance exercise interventions during and following cancer treatment: a systematic review
MDedge Hematology and Oncology
CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index
MDedge Hematology and Oncology
Utilization of radiotherapy services by a palliative care unit: pattern and implication
MDedge Hematology and Oncology
Predicting life expectancy in patients with advanced incurable cancer: a review
MDedge Hematology and Oncology